UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February 10~~March 6, 2026

DAMORA ~~GALECTO~~THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-39655	37-1957007
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(I.R.S. EmployerIdentification No.)
	75 State Street, Suite 100Boston, MA 02109(Address of principal executive offices, including zip code)
	(781) 281-9020(Registrant’s telephone number, including area code)
	Galecto, Inc.(Former name or former address, if changed since last report)

75 State Street, Suite 100

Boston, MA 02109

(Address of principal executive offices, including zip code)

(+45) 70 70 52 10

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trade Symbol~~TradingSymbol(s)		Name of each ~~exchange~~exchangeon on which registered
Common Stock, $0.00001 par value per share		~~GLTO~~DMRA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 12.~~01.~~02 ~~Entry~~Results ~~into~~of aOperations ~~Material~~and ~~Definitive~~Financial ~~Agreement~~Condition.

On ~~February 10~~March 9, 2026, ~~Galecto~~Damora Therapeutics, Inc., ~~(the~~formerly ~~“Company”)~~known ~~entered~~as ~~into~~Galecto, anInc. ~~underwriting agreement~~ (the “~~Underwriting Agreement~~Company”), ~~with~~issued ~~Jefferies~~a ~~LLC~~press ~~and Leerink~~release ~~Partners LLC~~announcing, asamong ~~the~~other ~~representatives~~things, of the ~~several~~Name ~~underwriters~~Change ~~named~~Amendment ~~therein~~ (~~the~~as ~~“Underwriters”~~defined below), ~~relating to the offer~~ and ~~sale (~~the ~~“Offering”)~~Symbol ofChange ~~14,473,685 shares of the Company’s common stock, par value $0.00001 per share~~ (~~the~~as ~~“Common~~defined ~~Stock”~~below), atwhich aindicates ~~public~~that ~~offering price of $19.00 per share. In addition,~~ the Company ~~granted~~had ~~the~~cash ~~Underwriters~~and acash ~~30-day~~equivalents ~~option (the “Option”) to purchase up to an additional 2,171,052 shares~~ of ~~its~~approximately ~~Common~~$535 ~~Stock~~million ~~on the same terms and conditions~~ as ~~the~~of ~~Common Stock sold in the Offering, which the Underwriters exercised in full on~~ February 1128, 2026.

The ~~net~~estimated ~~proceeds~~cash toand ~~the~~cash ~~Company~~equivalents ~~from~~amount ~~the~~is ~~Offering~~preliminary ~~are~~and ~~approximately $295.9 million~~unaudited, ~~which~~represents ~~includes~~management’s ~~the~~estimate ~~proceeds~~as ~~from~~of the ~~exercise~~date of ~~the~~this ~~Option~~report, ~~after~~and ~~deducting~~does ~~underwriting~~not ~~discounts~~present ~~and~~all ~~commissions~~necessary ~~and~~information ~~estimated~~for ~~offering~~a ~~expenses.~~complete ~~The~~understanding ~~net proceeds~~ of ~~this~~the ~~Offering~~Company’s ~~together~~financial ~~with~~condition ~~existing~~as ~~cash~~of ~~and~~February ~~cash~~28, ~~equivalents are expected to be sufficient to fund operations into Phase 3 development of DMR-001~~2026. The ~~Company~~ ~~has~~actual ~~based~~financial ~~this~~results ~~estimate on assumptions that~~ may ~~prove~~differ tomaterially befrom ~~incorrect, and~~ the ~~Company~~preliminary ~~could~~estimated ~~use~~financial ~~its available capital resources sooner than it currently anticipates~~information.

~~The~~In ~~Common~~accordance ~~Stock~~with ~~described~~General ~~above~~Instruction ~~was~~B.2 ~~offered~~of ~~pursuant~~Form to8-K, anthe ~~automatic~~information ~~shelf~~under ~~registration~~this ~~statement~~Item on2.02, ~~Form S-3~~including ~~(File~~Exhibit No99. ~~333-293343)~~1, ~~which~~shall ~~was~~not be deemed filed ~~with~~for ~~the~~purposes ~~U.S.~~of ~~Securities~~Section ~~and~~18 of the Securities Exchange ~~Commission~~Act of 1934, as amended (the “~~SEC~~Exchange Act”), onor ~~February 10,~~otherwise ~~2026~~subject ~~and~~to ~~automatically~~the ~~became~~liabilities ~~effective~~of ~~upon~~that ~~filing.~~section, Anor ~~final~~shall ~~prospectus~~such ~~supplement~~information ~~dated~~be ~~February 10,~~deemed ~~2026~~incorporated ~~relating~~by toreference ~~and~~in ~~describing~~any filing under the ~~terms~~Securities Act of ~~the~~1933, ~~Offering~~as ~~was~~amended ~~filed~~(the ~~with~~“Securities ~~the~~Act”), ~~SEC~~or onthe ~~February 11~~Exchange Act, ~~2026.~~except ~~The Offering~~as isexpressly ~~expected~~set toforth ~~close~~by onspecific ~~February 12,~~reference ~~2026.~~in such a filing.

InItem ~~the~~5.03 ~~Underwriting~~Amendments ~~Agreement, the Company agreed~~ to ~~indemnify~~Articles ~~the underwriters against certain liabilities, including liabilities under the Securities Act~~ of ~~1933,~~Incorporation ~~as amended,~~ or toBylaws; ~~contribute~~Change ~~payments that the underwriters may be required to make because of such liabilities. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified~~ in ~~its~~Fiscal ~~entirety by reference to the full text of the Underwriting Agreement, which is filed herewith as Exhibit 1~~Year.~~1 and incorporated by reference herein.~~

AOn ~~copy~~March 6, 2026, the Company filed with the Secretary of State of the ~~opinion~~State of ~~Gibson,~~Delaware ~~Dunn &~~an ~~Crutcher~~amendment ~~LLP~~to ~~relating~~its Amended and Restated Certificate of Incorporation to change the ~~validity~~name of the ~~shares~~Company offrom ~~Common~~“Galecto, ~~Stock~~Inc.” ~~issued~~to in“Damora Therapeutics, Inc.” (the ~~Offering~~“Name isChange ~~filed~~Amendment”). ~~herewith~~The asName ~~Exhibit~~Change 5Amendment became effective at 12:01 a.1m. Eastern Time on March 10, 2026.

~~Item~~The 9board of directors of the Company (the “Board”) approved the Name Change Amendment pursuant to Section 242 of the General Corporation Law of the State of Delaware.01 Pursuant to Section 242 of the Delaware General Corporation Law, stockholder approval was not required to approve or effect the Name Change Amendment. ~~Financial~~The ~~Statements~~Name ~~and~~Change ~~Exhibits~~Amendment will not in any way affect the voting or other rights that accompany the Company’s common stock, par value $0.00001 per share (“Common Stock”), or the validity or transferability of the shares of Common Stock currently outstanding.

The Common Stock will continue to be quoted on The Nasdaq Capital Market, but beginning with the opening of trading on March 10, 2026, trading is expected to be under the new symbol “DMRA” (d)the ~~Exhibits~~“Symbol Change”). There will be no change to the Common Stock’s CUSIP in connection with the Name Change Amendment.

Exhibit Number		Exhibit Description
1.1		Underwriting Agreement, by and among the Company and Jefferies LLC and Leerink Partners LLC, dated as of February 10, 2026
5.1		Opinion of Gibson, Dunn & Crutcher LLP
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

A copy of the Name Change Amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference.

~~SIGNATURES~~Item 7.01 Regulation FD Disclosure.

~~Pursuant~~On toMarch 9, 2026, the ~~requirements~~Company ofissued ~~the~~a ~~Securities~~press ~~Exchange~~release ~~Act~~announcing ofthe ~~1934,~~Name Change Amendment and the ~~Registrant~~Symbol ~~has~~Change, ~~duly~~a ~~caused~~copy ~~this~~of ~~report~~which tois befurnished ~~signed~~herewith onas ~~its~~Exhibit ~~behalf~~99.1 byand ~~the~~is ~~undersigned~~incorporated ~~hereunto~~by ~~duly~~reference ~~authorized~~herein.

In accordance with General Instruction B.2 of Form 8-K, the information under this Item 7.01, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.


Item 9.01	Financial Statements and Exhibits.

(d) Exhibits


Exhibit Number		Description of Document

3.1		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, filed March 6, 2026

99.1		Press Release, dated March 9, 2026

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	Damora Therapeutics, Inc.

Date: March 10, 2026	By:	/s/ Sherwin Sattarzadeh
		Sherwin Sattarzadeh
		Chief Operating Officer

Galecto, Inc.

Date: February 11, 2026

/s/ Sherwin Sattarzadeh

Sherwin Sattarzadeh

Chief Operating Officer

Filing Compare · Damora Therapeutics, Inc.